On October 15, 2019 Kleo Pharmaceuticals Inc., a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics, reported that its CEO Doug Manion, M.D., FRCP(C), will present at the 2019 BIO Investor Forum, which will be held at the Westin St. Francis Union Square in San Francisco on October 22-23rd (Press release, Kleo Pharmaceuticals, OCT 15, 2019, View Source [SID1234542287]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During his live presentation, Dr. Manion will provide an overview of Kleo’s development strategy for its pipeline of small molecule and synthetic peptide compounds that function similar to highly complex biologics, while offering multiple potential advantages. The overview will also outline Kleo’s key value drivers including the three proprietary technology platforms that drive in-house drug development and partnership opportunities, the multiple in-house and collaborative channels through which it is building its immuno-oncology pipeline and its discovery collaboration with PeptiDream. Human studies are anticipated in 2020 for Kleo’s first product candidate to move into the clinic, CD38-ARM, a CD38 targeting antibody recruiting molecule (ARM) to treat multiple myeloma.

Dr. Manion will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

Details of Kleo’s presentation are as follows:

Event:

2019 BIO Investor Forum

Date:

Tuesday, October 22, 2019

Time:

2:30 p.m. PDT

Location:

Room: Elizabeth A

Westin St. Francis Hotel

335 Powell Street

San Francisco, CA

The presentation will be webcast live and remain available for 90 days following the presentation. To access the webcast, please visit the News & Events section of Kleo’s website at kleopharmaceuticals.com/news-events/